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The treatment of hematologic malignancies by harnessing
immune responses has long been pursued. It is well accepted
that the success of allogeneic hematopoietic stem cell
transplantation (HSCT) as a treatment for hematologic
malignancies is due primarily to immunologic recognition
and elimination of recipient leukemia cells by donor T cells,
termed the graft-versus-leukemia (GVL) effect. Based on the
discovery and identiﬁcation of leukemia antigens, it is now
possible to target leukemia either by speciﬁc vaccination or
by adoptive transfer of in vitroegenerated antileukemia
cytotoxic T lymphocytes (CTLs).
Leukemia antigens can be categorized into 3 broad classes:
(1) ubiquitously expressed alloantigens, also known as minor
histocompatibility antigens (miHAs), widely expressed by
normal tissues in the recipient aswell as by leukemia cells and
capable of initiating both graft-versus-host disease (GVHD)
and GVL responses; (2) alloantigens, expressed uniquely by
cells of the hematopoietic system (tissue-restricted miHAs),
such as HA-1 and HA-2; and (3) leukemia antigens, including
leukemia-speciﬁc antigens, such as BCR-ABL in Philadelphia
chromosomeepositive leukemia, and overexpressed or
aberrantly expressed leukemia-associated antigens (LAAs),
such as proteinase 3, Wilms’ tumor 1, and the preferentially
expressed antigen of melanoma.
Previous studies have shown a temporal inverse rela-
tionship between circulating T cells directed against miHAs
or LAAs and minimal residual disease in patients with acute
and chronic leukemia after allogeneic HSCT, supporting
a role for these antigens in the GVL response [1,2]. This
review takes a bench-to-bedside approach to evaluating
strategies for active induction and passive transfer of tumor-
speciﬁc T cells in patients with hematologic malignancies.Posttransplantation Vaccination in Leukemia
Several different strategies of vaccination against leukemia
have been explored, including delivery of speciﬁc antigens
with peptide, protein, DNA, or RNA vaccines and induction of
nonspeciﬁc antileukemic responses using leukemic dendritic
cells and leukemia cells engineered to secrete granulocyteFinancial disclosure: See Acknowledgment on page S100.
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although eliciting convincing antileukemia immune
responses, have produced only anecdotal clinical responses
[3-6]. Amajor limitationof thevariousvaccinationapproaches
is related to the fact that most deﬁned leukemia antigens are
products of normal genes overexpressed or selectively
expressed in leukemia cells. The immune system is ﬁnely
balanced to distinguish foreign antigens from self antigens. In
effect, cancer vaccination aims to break tolerance to self and
elicit an “autoimmune” response. Thus, one of the major
hurdles for effective vaccination is overcoming the central and
peripheral tolerance to self antigens.
The existing T cell repertoire speciﬁc for self antigens is
limited to low-avidity T cells with limited recognition of
endogenously processed leukemia antigens [7]. Nevertheless,
vaccinationcanbeeffective, even though the response is limited
to low-avidity CTLs [8]. Attempts have been made to create
more immunogenic antigens throughmolecular manipulation.
Inserting an amino acid change in the peptide epitopemakes it
possible to produce an antigen that binds more strongly to the
relevantHLAmolecule and thushas ahigher chance of breaking
tolerance against self proteins [9]. Vaccination of patients with
hematologicmalignancieswithmodiﬁedHLA class I and class II
epitopes from the self-antigenWilms’ tumor 1 has been shown
to induce immune responses associated with evidence of clin-
ical response in some cases [4,5].
HSCT and Adoptive Immunotherapy
The intersection of HSCT and more speciﬁc immuno-
therapy based on the knowledge of deﬁned antigens offers
exciting opportunities to develop novel therapeutic
approaches. The profoundly lymphopenic environment
immediately after HSCT provides a favorable milieu for rapid
and extensive lymphocyte expansion, and facilitates immune
responses to weak self antigens [10]. The lymphopenic
environment allows strong expansion of antitumor T cells in
the presence of cytokines responsible for thymic-
independent homeostatic T cell proliferation, such as IL-7,
IL-15, and IL-21. Along with eradicating cells that may
suppress antitumor responses, such as regulatory T cells,
myeloid-derived suppressor cells, and tumor-associated
macrophages, lymphoid reconstitution of either donor or
host origin may overcome inherent defects in T cell signaling,
processing, or presentation and may strengthen the cos-
timulatory functions of antigen-presenting cells. BecauseTransplantation. Published by Elsevier Inc. All rights reserved.
K. Rezvani et al. / Biol Blood Marrow Transplant 19 (2013) S97eS101S98reconstitution of the T cell compartment in lymphopenic
hosts is regulated by peptides occupying MHC class I and II
molecules, there may be an opportunity to skew the T cell
repertoire at the time of T cell recovery by engaging the
available MHC class I and class II molecules with antigens of
particular interest. These observations imply that the ﬁrst
few months after HSCT offer a unique environment for
delivering GVL directed against both LAAs and miHAs
expressed by vaccination.
An alternative approach to HSCT may be a combination of
adoptive cell transfer and vaccination. In this setting,
patients can be treated with lymphodepleting therapies to
eliminate immunosuppressive cells and other lymphoid cells
that compete for T cell growth factors, such as IL-7 and IL-15.
The success of this approach was demonstrated in the
seminal study of Dudley et al. [11], which identiﬁed lym-
phodepletion as critical to the success of tumor-inﬁltrating
lymphocyte transfer in the treatment of melanoma. The
adoptively transferred T cells could be primed against
leukemia in vivo by vaccinating the patient (or the donor in
the setting of allogeneic HSCT), then collected and infused
after chemotherapy, as described by June et al. [12], or they
could be genetically modiﬁed in vitro or expanded ex vivo
before adoptive transfer.
Conclusions
Allogeneic HSCT continues to play a unique role in
achieving cure of hematologic malignancies. The vigorous
homeostatic proliferation of donor T cells after HSCT may
represent a hitherto underused window of opportunity for
immunotherapy. It is likely that a multifaceted approach to
immunotherapy involving HSCT, adoptive T cell transfer, and
vaccination will be the next step toward effective
immunotherapy.
AUTO-IMMUNOTRANSPLANTATION FOR LYMPHOMA
Introduction
The Stanford group have developed a strategy of thera-
peutic vaccination against lymphoma that they interdigitate
with conventional autologous HSCT (auto-HSCT). Autologous
tumor cells are activated ex vivo with a TLR9 ligand (CpG
oligonucleotide), irradiated, and then used as a vaccine to
induce a T cell immune response against the tumor in the
patient. The immune T cells are collected and then reinfused
into the patient immediately after auto-HSCT. The goal is
to allow the T cells to expand in the patient during the
immunologic recovery period andmediate immune rejection
of residual tumor. They refer to this approach as
immunotransplantation.
This strategy has several important features:
 Simplicity. No tumor antigens need be identiﬁed in
advance; instead, the whole tumor cell is the vaccine.
The activation step uses an “off-the-shelf,” chemically
deﬁned substance (CpG oligonucleotide) with a track
record of safety and effectiveness as an immune stimu-
lant in lymphoma [13-15].
 Feasibility. The entire treatment strategy was applied
under their investigational new drug without adverse
effects.
 Homeostatic T cell proliferation. They have shown in
preclinical models that adoptively transferred T cells
expand during the immediate posttransplantation
period, and that Teffector cells do so preferentially over T
regulatory cells, resulting in powerful therapeutic effects.Phase I/II Study of Immunotransplantation for Patients
with Mantle Cell Lymphoma
The Stanford group then initiated a clinical trial for
patients newly diagnosed with mantle cell lymphoma (MCL),
and have accrued 35 patients during the trial’s ﬁrst 3 years.
Sixteen of these patients completed the entire treatment
program. They deﬁned a target of 85% freedom from
minimal residual disease (MRD) at 1 year. They have devel-
oped a sequencing-based platform for MRD quantiﬁcation in
lymphoid malignancies. Using universal primer sets, rear-
ranged IgH variable (V), diversity, and joining (J) gene
segments from genomic DNA are ampliﬁed. To minimize the
risk of somatic hypermutation interfering with detection of
a cancer sequence, each IgH sequence is ampliﬁed by
different sets of multiplex PCR primers in the 3 framework
regions of the V segments and a common J segment primer.
Ampliﬁed products can be sequenced to obtain more than 1
million reads and are analyzed using algorithms for clono-
type determination. Tumor-speciﬁc clonotypes are identiﬁed
for each patient based on their high frequency in the original
tumor specimen. Quantitative MRD levels are then deter-
mined in serial samples of peripheral blood using spiked-in
reference sequences. The test has a sensitivity of 1 tumor
cell per 1 million leukocytes. This technology has also been
extended to immunoglobulin light chain receptors and TCRs.
To quantify T cell responses to tumor vaccinations, the same
samples are used for ampliﬁcation, sequencing, and analysis
of the entire TCR-b repertoire, allowing for the assessment of
T cell immune responses to the vaccine.
To date, they have analyzed serial samples from 13
patients with MCL who received the protocol of induction
chemotherapy, vaccination, and HSCT followed by vaccine-
primed T cell infusions and booster vaccinations. MRD was
assayed in blood samples immediately after transplantation
in 3 patients, 2 of whom ultimately relapsed. In these 2
cases, disease was detected by sequencing at 14 months
and 4.5 months before detection by radiologic techniques.
Clinical relapse in the second patient was originally
restricted to the central nervous system; however, lymph
node relapse occurred later. The third patient has shown no
signs of clinical relapse. The remaining 10 patients were
MRD-negative at 1 year after HSCT and have shown no
signs of clinical relapse with a median follow-up of >24
months.
To identify T cells speciﬁc to the vaccination, clonotypes
that were highly enriched (>10 times) in an in vitro tumor-
stimulated culture were searched. Such clonotypes were
identiﬁed in 2 of 3 patients assayed. Enrichment of these
same clonotypes was also seen in these patients after
vaccinations and boosters, adding to the evidence supporting
their direction against the vaccine. The frequency of these
clonotypes was increased signiﬁcantly after the boost
compared with a set of frequency-matched unrelated clo-
notypes (P < 2.5  106).Conclusions
The Group at Stanford conclude that their auto-
immunotransplant procedure shows promise in patients with
MCL. Using a high-throughput sequencing method for MRD,
77%of patients (10 of 13)were negative at the landmarkdate of
1 year posttransplantation. Continued follow-up formolecular
and clinical relapse is ongoing. T cell repertoire analysis iden-
tiﬁed clonotypes responding to the vaccination in some
patients, and follow-up analyses will determine whether the
K. Rezvani et al. / Biol Blood Marrow Transplant 19 (2013) S97eS101 S99presence of these clonotypes correlates with clinical outcomes
in patients with MCL.
T CELL ADOPTIVE IMMUNOTHERAPY FOR
HEMATOLOGIC MALIGNANCY
Introduction
The impetus to develop T cellebased cell therapy for
treatment of hematologic malignancies comes from thewell-
grounded observation that allogeneic T lymphocytes are
capable of potent graft-versus-leukemia (GVL) effects in SCT
recipients [16]. Although murine studies in the 1950s
demonstrated that a GVL effect could be induced after bone
marrow transplantation, the reality of a potent GVL effect in
humans ﬁrst achieved general acceptance after 2 critical
publications. Theﬁrst, from the Center for International Blood
and Marrow Transplantation Research in a large patient
population, reported that posttransplantation relapse rate
was lowest in recipients of T cellereplete HSCT compared
with recipients of T celledepleted HSCT, and was even lower
when T cellereplete HSCT was accompanied by both acute
and chronic GVHD. The second study, from Kolb et al. [17],
found that donor lymphocyte infusion (DLI) achieved durable
remission in patients with chronic myelogenous leukemia
(CML) who relapsed after HSCT. In the 1990s, attempts were
made to reﬁne Tcell therapy for the treatment andprevention
of relapse. Studies showed some separation of GVHD andGVL
when CD4 T cells were used in DLI therapy. Combining DLI
with IFN-a appeared to provide some reduction of in relapse
rate in patients with CML. Other investigators reported some
efﬁcacy of using DLI with granulocyte macrophage colony-
stimulating factor as a means of up-regulating antigen
presentation by leukemia cells. In Milan, Lupo-Stanghellini
et al. [18] inserted a suicide gene into T cells destined for DLI
to eliminate GVHD. Another group explored the preemptive
depletion of alloreacting T cells from the graft inoculum [19].
Falkenburg et al. [20] were the ﬁrst to demonstrate that CTLs
generated by repeatedly stimulating donor lymphocyteswith
CML cells can beused to treat patientswith relapsed leukemia
after HSCT. A patient relapsing after HSCT who had residual
CML disease was given 3 infusions of T cell lines generated
in vitro using his own leukemic cells, resulting in prompt and
persistent eradication of leukemia [20]. In recent years, the
technology for selecting and expanding leukemia antigen-
speciﬁc T cells has improved to a level where clinical-grade
CD4 and CD8 T cells that recognize either miHAs [21] or
LAAs [22] cannowbe created. Strategies havebeendeveloped
to enhance the cytotoxicity of leukemia-speciﬁc T cells by
redirecting T cells using genetically inserted high-avidity
leukemia-speciﬁc TCRs [23] or targeting the malignant cell
with a monoclonal antibody either attached to a CD3 mole-
cule (bispeciﬁc antibodies) [24] or as a chimeric molecule
triggering T cell activation [25] (Table 1). This review
summarizes the essential biology of T celleleukemia inter-
actions, the techniques used to generate leukemia-reactive T
cells for the clinic, and the main challenges facing T cell
therapy for hematologic malignancies.
CHALLENGES TO THE EFFECTIVENESS OF ADOPTIVE T
CELL TRANSFER
Persistence and Function in Vivo
In recent years, we have gained a much better under-
standing of the dynamics and functional segregation of the
postthymic T cell compartment, which for therapeutic
purposes can be segregated into “early” T cells, which have
great self-renewal potential and longevity, and “late” end-effector T cells, which are cytotoxic but have very limited
survival. T cell cultures tend to senesce into end-stage
effectors, rendering T cell infusions short-lived and ineffec-
tive. By selecting “early” cells for expansion (CD45RA naïve
cells, or CD62þCD27þCD57- central memory cells), modifying
culture conditions, and reducing the duration of in vitro
expansion, it is possible to create much longer-lived cell
products. Another important principle learned from the
transfer of virus-speciﬁc T cells is the beneﬁt of generating
both CD4 and CD8 T cell lines to provide CD4 help, which
increases the persistence of CD8 cells and provides addi-
tional cytotoxicity from cytotoxic CD4 cells, including the
highly tumor-reactive Th17 phenotype. Much remains to be
learned about the conditions governing survival distribution
and effector function of adoptively transferred CTLs in vivo.
Recipient Milieu
Of equal importance is the milieu into which therapeutic
T cells are transferred. Numerous studies have demonstrated
that the delivery of T cells into a lymphopenic environment
enhances their in vivo expansion and persistence through
the release of lymphokines, including IL-15. Ideally, T cells
should be transferred into a non-immunosuppressed recip-
ient. Steroid therapy carries the risk of ablating infused T
cells; however, the degree to which immune function is
blunted by calcineurin inhibitors is unclear. Regulatory Tcells
can also be anticipated to reduce the potency of adoptively
transferred Tcells. Although antigen-speciﬁc Tcells appear to
home to the bone marrow, little is known about the distri-
bution of CTLs to extramedullary sites, which are notable
sites of relapse after allogeneic SCT. In tumor immunology
and lymphomas and myeloma, much progress has been
made in characterizing features of the tumor microenvi-
ronment that nurture malignant cells and protect them from
immune attack; however, less is known about the role of the
marrow microenvironment in sheltering leukemia from
immune attack. More studies are needed in this area.
Immune Escape and Strategies to Overcome it
Tumor cells have developed various mechanisms to
escape from the host’s immune system and are also able to
overcome chemotherapeutic or immunotherapeutic thera-
pies, rendering these therapies ineffective in treating and
eradicating leukemia cells. A major obstacle to adoptive T cell
therapy is the ability of malignant cells to change expression
of antigens by down-regulation mechanisms owing to
selective pressure or selective elimination of cells expressing
the targeted antigen. Acute myelogenous leukemia cells can
down-regulate MHC expression notably after haploidentical
HSCT when the relapsed leukemia loses expression of the
entire mismatched MHC haplotype [26]. Leukemia can also
evade T cell attack by becoming resistant to perforin and
granzyme, preventing immune synapse formation and
down-regulating tumor antigen expression. The function of
adoptively transferred T cells may be improved by gene
modiﬁcation strategies [23,27].
Moving from the Ivory Tower into the Marketplace
Cell therapies in general, and adoptive T cell therapy in
particular, present unique challenges that discourage
corporate efforts to develop clinical-grade cell products [27].
The main blocks to the wider application of adoptive T cell
therapy and some of the solutions to the impasse are
summarized below.
Table 1
Approaches to Generating Leukemia-Speciﬁc CTLs in SCT Recipients
Strategy Technique
Noneantigen-deﬁned
Negative selection of
GVHD-reactive T cells
Suicide gene insertion; selective
allodepletion
Generation of leukemia-
reactive T cells
Leukemic antigen-presenting cells
for culture expansion; marrow-
inﬁltrating lymphocytes
Antigen-deﬁned
Expansion of miHA-
speciﬁc T cells
MHC class I and class II miHAs
Expansion of leukemia
antigen-speciﬁc T cells
LAA peptides; gene insertion into
dendritic cells
Antigen-modiﬁed T cells
Gene-modiﬁed CD19 chimeric antigen receptors
TCR gene insertion Gene insertion into carrier T cells
Bispeciﬁc antibodies CD19/CD3 or CD22/CD3 antibodies
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One of the immediate challenges is to move forward with
T cell therapy beyond small case series illustrating proof of
principle to larger phase II and phase III trials. If clinical trials
with leukemia-speciﬁc T cells can show success similar to
that seen with the use of adoptive T cell therapy for virus
infections after HSCT or the striking success of chimeric
antigen receptor cells in chronic lymphocytic leukemia and
also demonstrate cost-effectiveness over existing treat-
ments, we can anticipate greater enthusiasm for T cell
therapy. In turn, this would do much to bridge the gap (the
“valley of death” described by Malcolm Brenner [personal
communication]) between the initial development of
sophisticated cell therapies in ivory tower academic insti-
tutions to the uptake of the concept by manufacturers
capable of widely disseminating the cell product.
Many of the strategies currently under development
require the creation of a unique product from a donor for
a speciﬁc patient. Generalizability is limited by HLA restric-
tion and the speciﬁc array of antigens present in the malig-
nancy. Approaches that may possibly overcome these
constraints include the development of multiantigen-
speciﬁc T cells targeting common LAAs and conferring
broad applicability across many malignancies and the use of
“off the shelf” third-party T cells partially HLA matched with
the recipient, similar to third-party virus-speciﬁc T cells,
which have proven efﬁcacy. The insertion of a TCR into the
donor T cells and the redirection of T cells through TCR
insertion, use of bispeciﬁc antibodies, or chimeric antigen
receptors also hold promise for generalizing T cell therapy.
Quicker, Simpler, and Safer Cell Production
Culture approaches have improved considerably in
recent years as conditions have been optimized. However,
cells are typically manufactured in good manufacturing
practice (GMP) facilities, which are expensive to construct
and operate, restricting the onsite production of antigen-
speciﬁc or modiﬁed T cells to only a few centers in the
United States. One successful commercial model involves
setting up a central cell factory that processes leukapheresis
collections from hospitalized patients and ships the manu-
factured T cell product back to the users (compare the
dendritic cell approach used in the product sipuleucil-T).
Alternatively, in the case of third-party T cells, the product
can be produced commercially and delivered off the shelf to
the users. Ultimately, the greatest ﬂexibility would come
from the creation of complete benchtop cell factories, inwhich donor cells are infused into “black boxes” that have
cell selection, antigen stimulation, culture expansion, and
product delivery capability and whose GMP grade internal
workings are separated from the environment, replacing the
need for a classical GMP unit. Although working devices
that can be operated in any blood bank are some years off,
several commercial manufacturers are currently working
toward this goal.ACKNOWLEDGMENT
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